

Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper

Antonio Simone Laganà^{a,b} Andrea Romano^c Arne Vanhie^{d,e}
Celine Bafort^{d,e} Martin Götte^f Lauri A. Aaltonen^{g,h,i} Aymara Mas^j
Christine De Bruyn^{e,k} Thierry Van den Bosch^{e,l} An Coosemans^m
Stefano Guerriero^{n,o} Sergio Haimovich^{p,q} Vasilios Tanos^{r,s}
Marlies Bongers^{c,t} Fabio Barra^{u,v} Ayman Al-Hendy^{w,x} Vito Chiantera^{b,y}
Umberto Leone Roberti Maggiore^z

^aUnit of Obstetrics and Gynecology, “Paolo Giaccone” Hospital, Palermo, Italy; ^bDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy; ^cDepartment of Obstetrics and Gynecology, GROW-School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands; ^dDepartment of Obstetrics and Gynaecology, Leuven University Fertility Center, University Hospitals Leuven, Leuven, Belgium; ^eDepartment of Development and Regeneration – Woman and Child, KU Leuven, Leuven, Belgium; ^fDepartment of Gynecology and Obstetrics, Münster University Hospital, Munster, Germany; ^gDepartment of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland; ^hApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland; ⁱiCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland; ^jCarlos Simon Foundation - INCLIVA Health Research Institute, Valencia, Spain; ^kDepartment Obstetrics and Gynaecology, University Hospital Antwerp, Edegem, Belgium; ^lDepartment of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium; ^mDepartment of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; ⁿCentro Integrato di Procreazione Medicalmente Assistita (PMA) e Diagnostica Ostetrico-Ginecologica, Azienda Ospedaliero Universitaria-Policlinico Duilio Casula, Monserrato, Italy; ^oDepartment of Surgical Sciences, University of Cagliari, Cagliari, Italy; ^pDepartment of Obstetrics and Gynecology, Laniado University Hospital, Netanya, Israel; ^qAdelson School of Medicine, Ariel University, Ariel, Israel; ^rDepartment of Obstetrics and Gynecology, Aretaeo Hospital, Nicosia, Cyprus; ^sDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus; ^tDepartment of Obstetrics and Gynecology, Máxima Medical Centre, Veldhoven, The Netherlands; ^uUnit of Obstetrics and Gynecology, P.O. “Ospedale del Tigullio” - ASL4, Metropolitan Area of Genoa, Genoa, Italy; ^vDepartment of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; ^wDepartment of Obstetrics and Gynecology, University of Chicago, Chicago, USA; ^xDepartment of Surgery, University of Illinois at Chicago, Chicago, USA; ^yUnit of Gynecologic Oncology, National Cancer Institute - IRCCS - Fondazione “G. Pascale”, Naples, Italy; ^zGynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Keywords

Uterine fibroids · Sarcomas · Biomarkers · Ultrasound · Treatment · Uterine myomectomy · Hysteroscopy · Laparoscopy

Abstract

Background: Uterine fibroids are benign monoclonal tumors originating from the smooth muscle cells of the myometrium, constituting the most prevalent pathology within the female genital tract. Uterine sarcomas, although rare, still represent a diagnostic challenge and should be managed in centers with adequate expertise in gynecological oncology. **Objectives:** This article is aimed to summarize and discuss cutting-edge elements about the diagnosis and management of uterine fibroids and sarcomas. **Methods:** This paper is a report of the lectures presented in an expert meeting about uterine fibroids and sarcomas held in Palermo in February 2023. **Outcome:** Overall, the combination of novel molecular pathways may help combine biomarkers and expert ultrasound for the differential diagnosis of uterine fibroids and sarcomas. On the one hand, molecular and cellular maps of uterine fibroids and matched myometrium may enhance our understanding of tumor development compared to histologic analysis and whole tissue transcriptomics, and support the development of minimally invasive treatment strategies; on the other hand, ultrasound imaging allows in most of the cases a proper mapping the fibroids and to differentiate between benign and malignant lesions, which need appropriate management. **Conclusions and Outlook:** The choice of uterine fibroid management, including pharmacological approaches, surgical treatment, or other strategies, such as high-intensity focused ultrasound (HIFU), should be carefully considered, taking into account the characteristics of the patient and reproductive prognosis.

© 2024 S. Karger AG, Basel

Introduction

This is a brief report of the lectures presented in an expert meeting about uterine fibroids (known also as leiomyomas or myomas) and (leiomyo)sarcomas, held in Palermo in February 2023. Each section reflects the content of one lecture presented at the meeting; each one of the authors revised the text for amendments and gave final approval for its publication.

Somatic Mutation Landscape in Fibroids

The first exact genetic driver change in fibroids was described in 1995 when – guided by cytogenetic analyses – Schoenmaker et al. [1] scrutinized recurring translocations resulting in overexpression of the oncogenic transcription factor HMGA2. The availability of high-throughput sequencing 15 years later allowed systematic nucleotide-level analyses and has resulted in the identification of a small number of mutually exclusively mutated fibroid driver genes. In 2011, specific MED12 gene mutations, in particular in codon 44, were discovered in a large proportion of uterine fibroids [2]. In subsequent studies, the proportion of mutated tumors has varied, likely due to sample selection bias as MED12 fibroids tend to be smallish in size. In an extensive sample set of 2,263 tumors exceeding 1 cm in diameter, 77% of fibroids carried a MED12 mutation [3]. These mutations disrupt the interaction between MED12 and CDK8 [4] and cause tumorigenic changes in the landscape of the regulatory genome and transcriptome [3, 5]. More rarely, mutations occur in fumarate hydratase [6, 7], as well as genes encoding proteins of the SRCAP complex [3] and neddylation genes [8]. A deletion at the COL4A5/COL4A6 locus, resembling one observed in germline of patients with Alport syndrome with leiomyomatosis, drives uterine fibroids by upregulation of near-by growth factor gene IRS4 [9]. Large chromosomal imbalances contribute to genesis of fibroids, 7q deletions targeting at least CUX1 transcription factor being the most frequent event [1, 9]. Moreover, other genetic aberrations have been reported in fibroids, albeit as rare events. The driver genes carry important clues to pathogenesis of fibroids. Most lesions arise from aberrant chromatin function, and particular areas poised to change their transcriptional status are commonly affected [3]. Myometrium is highly responsive to external cues such as hormonal and environmental factors associated with menstrual cycle and pregnancy, and poised chromatin can be envisioned to bear exceptional importance in the homeostasis of myometrial cells. Such plasticity gone awry could be a powerful facilitator of fibroid development, perhaps explaining the frequent occurrence of the condition.

What Does Single-Cell Transcriptomics Tell Us about Fibroids?

The clinical symptoms and morphological/histological signs of rare uterine sarcomas overlap with those of uterine fibroids. This convergence renders the discrimination between malignant and benign

myometrial tumors a challenging aspect of the diagnostic process [10].

Omic-based approaches that categorize uterine fibroids and sarcomas based on their genomic, epigenomic, and transcriptomic profiles have prompted the development of a new molecular classification system [11–13]. Unfortunately, most studies involve the evaluation of whole tissue samples, and inherent heterogeneity within and between tumors limits any mechanistic and therapeutic insight [14, 15]. Innovative technologies such as single-cell RNA sequencing, single-cell proteomics, and spatial transcriptomics have supported the creation of distinctive identities for each cell type as well as the detection of novel cell types and the identification of their functions in specific areas within organs [16, 17]. Overall, these advancements provide a better understanding of the cellular and molecular heterogeneity of various cell types.

Recently, single-cell transcriptomics and proteomics allowed to create a multi-omic profile of uterine fibroids and matched myometrium to understand the complex molecular processes underpinning tumorigenesis [10]: cell integration through single-cell myometrium anchors identified five biologically relevant cell clusters (supported by 52,909 cells), which included smooth muscle, endothelial, fibroblast, and perivascular cells; spatial transcriptomics demonstrated specific relationships between cells and their relative locations within the tissue. Interestingly, while uterine fibroids and matched myometrium possessed broad similarities in cellular composition, they displayed differential gene expression compared to each studied cell population. These data also provided evidence for the dysregulation of MAPK, PI3K-Akt, and proteoglycan pathways in smooth muscle, endothelial, fibroblast, and perivascular cell types.

Overall, molecular and cellular maps of uterine fibroids and matched myometrium may enhance our understanding of tumor development compared to histologic analysis and whole tissue transcriptomics and support the development of minimally invasive treatment strategies.

Liquid Biopsy Biomarkers in Uterine Sarcoma

A liquid biopsy is easy, less invasive, and can better capture tumor heterogeneity as compared to one single tissue biopsy [18]. Blood-based liquid biopsies can focus on circulating tumor cells, cell-free circulating tumor DNA, microRNA, noncoding RNA, circulating immune

cells, extracellular vesicles, and proteins. An overview on liquid biopsies in uterine sarcoma has recently been published [19]. Currently, the blood-based liquid biomarkers that can be employed in clinical practice are lactate dehydrogenase (LDH), cancer-antigen 125 (CA-125), and neutrophil-to-lymphocyte ratio (NLR).

LDH, as a final step in anaerobic glycolysis, is upregulated through oncogenes (biological phenomenon known as Warburg effect). LDH levels can also be increased in noncancerous conditions, such as tissue injury, necrosis, hypoxia, hemolysis, myocardial infarction, and hepatitis [20]. Six out of the eight retrospective studies report an increased level of LDH in uterine sarcoma. There is a substantial overlap in LDH levels between uterine sarcomas and degenerated or atypical uterine fibroids [21].

CA-125 is a known biomarker for ovarian cancer, but CA-125 levels are also raised in benign pathology including endometriosis or infection, and during pregnancy. Only three out of six retrospective studies show a significant increase in CA-125 levels in uterine sarcoma cases. CA-125 levels in the early stages of leiomyosarcoma overlap with those in uterine fibroids [21, 22].

The interaction between cancer cells and immune cells (immunoediting) [23] is reflected by the NLR, which mirrors the balance between immunosuppression and immune stimulation. A high NLR has been associated with adverse overall survival [24]. So far, three retrospective studies have shown the potential of NLR in distinguishing uterine sarcoma from uterine fibroids [21]. Although, based on retrospective studies, LDH and NLR are potentially useful markers in the diagnosis of a uterine sarcoma, there is a strong need for prospective studies on liquid biopsy biomarkers validating their role in clinical practice.

Uterine Fibroids and Sarcomas: Diagnosis and Classification

Three distinct categories of myometrial lesions exist, encompassing benign entities such as fibroids and adenomyosis, alongside malignant sarcomas. The correct differentiation between fibroids and sarcomas is crucial for the patients' management and prognosis.

Fibroids are very common (>50%), benign, and may either be managed expectantly or, in case of symptoms, medically or by (minimally invasive) surgery, minimizing surgical, cosmetic, and psychological morbidity. Uterine sarcomas are rare (5/10,000), but highly malignant requiring prompt and radical surgery, taking care to avoid any spilling of cancer cells into the abdominal cavity [25].




Fig. 1. FIGO staging of uterine fibroids (adapted from Munro et al. [27]).

On ultrasonography, fibroids are well-defined, usually round-shaped lesions [26]. Often, multiple fibroids are present. The location within/adjacent to the myometrium is reported according to the FIGO (International Federation of Gynecology and Obstetrics) classification [27]: from a totally intracavitary FIGO type 0 lesion to a pedunculated subserous FIGO type 7 fibroid (Fig. 1). The number of lesions, their size (measured in three perpendicular planes), their location (anterior, posterior, fundus, left, right), and the proximity of the uterine artery should be recorded. A precise mapping of the fibroid is important for optimal follow-up or to decide on the surgical approach.

On ultrasound scan, the echogenicity of a well-defined myometrial lesion may be uniform (hypoechoic, isoechoic, or hyperechoic as compared to the adjacent myometrium) or non-uniform (heterogeneous, with echogenic areas or calcifications, or with [irregular] anechoic [cystic] areas). Often, shadowing is present from the edge of the lesion (edge shadow) or behind the lesion (internal shadows). Internal shadows may be subtle, fan-shaped, or strong and obliterating any retrolesional structure.

At color/power Doppler examination, fibroids typically present circumferential vascularization. Internal vascularization may also be present and varies from absent/low grade to extensive. Internal vascularization is correlated with the fibroid's growth potential [28]. As opposed to fibroids, in adenomyosis, the lesion is often ill-defined, and the vascular pattern is typically translesional, with vessels crossing the adenomyotic area.




Fig. 2. Schematic illustration of the ultrasonographic features of fibroids (top) and uterine sarcomas (bottom).

Uterine sarcomas are often large or fast-growing, solitary, oval-shaped, or lobular lesions with inhomogeneous echogenicity [25, 29, 30]. Calcifications and fan-shaped shadowing are uncommon. Signs of central necrosis with formation of irregular cystic areas are highly suspicious for a malignant myometrial lesion. At color/power Doppler examination, sarcomas are often – at least partly – highly vascularized with an irregular/chaotic vascular pattern (Fig. 2; Table 1).

Diagnosis of Malignant Disease prior to Surgery by Imaging

A standardized sonographic approach to myometrial lesions should be always performed according to MUSA (Morphological Uterus Sonographic Assessment) criteria [26]. Although there is an excellent intra- and inter-rater agreement in the sonographic assessment of uterine

Table 1. Ultrasonographic features of fibroids and uterine sarcomas

Feature	Fibroid	Leiomyosarcoma
Number	Multiple	Solitary
Shape	Round	Oval/lobulated
Echogenicity	Calcifications	Inhomogenous
Fan-shaped shadowing	Frequent	Rare
Irregular cystic areas central necrosis	Rare	Frequent
"Cooked" appearance	No	Frequent
Vessels	Circumferential flow	Irregular vessels Score 3–4
Size	Variable	≥8 cm Fast-growing

fibroids [31], their ultrasonographic appearance can vary significantly due to the wide range of histologic variants in particular in cases of degenerated fibroids.

This unusual appearance can simulate the presence of sarcoma. As a matter of fact, differential diagnosis between uterine fibroids and sarcomas can be particularly challenging [32, 33]. Ultrasonographic suspicion features could be of particular importance in these cases such as the presence of large tumors, nonhomogeneous echogenicity, internal irregular cystic areas, rich and intralésional vascularization, and absence of shadowing or calcifications [30]. Uterine fibroids may resemble uterine sarcomas in some cases. In a recent published study, Cabezas et al. [34] conclude that approximately 5% of benign uterine fibroids may exhibit sonographic suspicion of sarcoma based on Ludovisi et al. [30] study. Although it is a small percentage, it is not negligible.

Magnetic resonance imaging is also a useful diagnostic tool [35], which could be of particular importance in preoperative mapping when the uterus extends beyond the pelvis and the use of standard ultrasonography is limited or when the ultrasonographic appearance is suspect based on Ludovisi et al. [30] criteria. The appearance of sarcomas is variable including large heterogeneously enhancing mass, with central T2 hyperintensity indicative of necrosis, but also homogeneously low-signal mass, similar to a fibroid [35]. Moreover, also the 18-fluoro-d-glucose positron emission tomography has been attempted as a diagnostic tool and could eventually be useful; however, current data are limited [36].

Based on a consensus conference on the management of uterine sarcomas published on behalf of SIGO (Italian Society of Obstetrics and Gynecology) [37], we suggest,

although no radiological criteria to differentiate atypical fibroids from uterine sarcomas are definitively established, that a myometrial lesion with "suspicious" signs for sarcoma at ultrasound requires further diagnostics.

Pharmacological Treatments of Uterine Fibroids

Medical management primarily aims to reduce heavy menstrual bleeding (HMB) and pain (dysmenorrhea, chronic pelvic pain) due to uterine fibroids (Table 2). First-line symptomatic medical management is based on the use of nonhormonal medical options such as non-steroidal anti-inflammatory agents and tranexamic acid due to their general availability, low cost, and limited adverse effects. In general, long-term hormonal medical treatment aims to improve symptoms due to uterine fibroids in patients without immediate desire for pregnancy (as these drugs interfere with ovulation) or in patients without a desire for pregnancy wishing to avoid or postpone surgical treatment [38].

Combined estrogen-progesterone oral contraceptives and progestins are hormonal options that can be used cyclically or continuously in the form of pills, vaginal rings, or transdermal patches. These drugs act by keeping the endometrium thin, thereby decreasing the amount of endometrial shedding during the menstrual cycle. Although these drugs are well tolerated, women should be informed of treatment-related potential adverse effects, such as nausea, headache, and irregular bleeding [39]. The levonorgestrel-releasing intrauterine device causes amenorrhea and/or improvement of menorrhagia and anemia in up to 50–60% of patients with HMB due to uterine fibroids at 6–12 months [40].

Table 2. Pharmacological strategies for uterine fibroids

Drug class	Mechanism of action	Advantages	Disadvantages
Nonsteroidal anti-inflammatory drugs	Inhibition of the enzyme cyclooxygenase and lowering the production of pro-inflammatory prostaglandins	<ul style="list-style-type: none"> • Effective in improving dysmenorrhea and pelvic pain • Not expensive 	<ul style="list-style-type: none"> • Mainly action on pain symptoms, but it does not regularize the menstrual cycle • Contraindicated in women with known hypersensitivity to this class of medications, active gastric or peptic ulcers, or advanced renal disease
Tranexamic acid	Prevention of fibrin degradation at the level of the plasminogen lysine receptor site, favoring procoagulant mechanisms which lead to a reduction in menstrual blood flow	<ul style="list-style-type: none"> • Effective in improving HMB • Not expensive 	<ul style="list-style-type: none"> • Mainly action on current bleeding, but it does not regularize the menstrual cycle • Possible onset of adverse effects including gastrointestinal and musculoskeletal symptoms • Contraindicated for patients with color blindness, active bleeding, and history of intravascular clotting
Estroprogestins and progestins	Maintenance of a thin endometrium and decrease of the amount of endometrial shedding during the menstrual cycle	<ul style="list-style-type: none"> • Not expensive • Multiple routes of administration are available (pills, vaginal rings, or transdermal patches) 	<ul style="list-style-type: none"> • Need a review of medical eligibility criteria (age, smoking, history of venous thrombosis, and migraines with aura) • Not effective in reducing fibroid size or characteristics • Higher LNG-IUD expulsion rate (especially with fibroids larger than 3 cm)
UPA	Action at the level of peripheral progesterone receptors on myomas by inducing cellular apoptosis, inhibiting proliferation of the fibroid, and thinning the endometrial lining	<ul style="list-style-type: none"> • Effective in inducing a 25–50% of fibroid shrinkage and highly effective in obtaining a decrease of uterine bleeding with an amenorrheic status (robust evidence) • Oral administration 	<ul style="list-style-type: none"> • As anovulation is seen in 80% during UPA treatment, the use of a reliable form of birth control (contraception) is recommended • Contraindicated for patients with asthma and liver impairment • Expensive
GnRH agonists	After an initial stimulation, binding to the GnRH receptor, block of endogenous GnRH activity, and direct suppression of LH and FSH production	<ul style="list-style-type: none"> • Effective in inducing a 25–50% of fibroid shrinkage and highly effective in obtaining a decrease of uterine bleeding with an amenorrheic status within 3 months of treatment initiation (elevate scientific evidence) • Monthly or trimestral schedule of administration 	<ul style="list-style-type: none"> • Not oral route of administration • Expensive • Relevant rate of AEs (i.e., hot flushes, mood swings, vaginal dryness, decreased libido, sleep disturbances), and bone mineral density loss without ABT

Table 2 (continued)

Drug class	Mechanism of action	Advantages	Disadvantages
GnRH antagonists	Rapid binding to the GnRH receptor, blocking endogenous GnRH activity, and directly suppressing LH and FSH production	<ul style="list-style-type: none"> • Oral route of administration • Possibility of multiple doses for each drug (low and high dose) with or without ABT. • Avoidance of the initial flare of GnRH agonists • Lower hypoestrogenic impact than GnRH agonists 	<ul style="list-style-type: none"> • Expensive • ABT necessary for alleviating hypoestrogenic- related AEs (i.e., hot flushes, mood swings, vaginal dryness, decreased libido, sleep disturbances), particularly if they are given at higher dose for long period • The need of a concomitant reliable form of birth control is controversial
Aromatase inhibitors	Inhibition of the aromatization of androgens to estrogens which results in thinning of the endometrial lining and reduced menstrual bleeding	<ul style="list-style-type: none"> • Oral route of administration 	<ul style="list-style-type: none"> • Low scientific evidence to support their use • Relevant rate of AEs (i.e., myalgia, osteoporosis)

ABT, add-back therapy; AE, adverse effect; LNG-IUD, levonorgestrel-releasing intrauterine device; UPA, ulipristal acetate; GnRH, gonadotropin-releasing hormone.

GnRH agonists have traditionally been used to induce amenorrhea in most women (>98%) with uterine fibroids, also leading to a 35–65% decrease in fibroid size within 3 months of treatment initiation. GnRH agonists have mainly been used as presurgical therapy for uterine fibroids. In fact, their use has been shown to improve both preoperative and postoperative hemoglobin levels, reduce operative time, and shorten the duration of hospital stay [41]. The main drawback of GnRH treatment is the induced hypoestrogenic state, which can cause menopause-related side effects and lead to a loss of bone mineral density. These adverse effects can be reduced by adding appropriate add-back therapy (ABT), especially for treatments with GnRH agonists lasting longer than 6 months [42]. Ulipristal acetate (UPA; 5 mg/day; only approved in Europe) is a selective progesterone receptor modulator, which has been initially approved for the pretreatment therapy of uterine fibroids [43]. UPA acts at the level of peripheral progesterone receptors by inducing apoptosis, inhibiting cellular proliferation of the fibroid, and thinning the endometrial lining. UPA has been associated with 25–50% fibroid shrinkage and greater than 90% uterine bleeding control in randomized control (PEARL and VENUS) trials. However, this drug faced criticism due to its temporary suspension in 2017 and 2020 after an apparent association with liver injury. Currently, the European Medicines Agency (EMA) has restricted UPA use as long-term intermittent treatment in

women who were not eligible for surgery. Before, during, and after cessation of this therapy, liver function needs to be evaluated monthly [44].

GnRH antagonists represent a relatively new alternative for the treatment of moderate to severe symptoms of uterine fibroids. The advantages of these drugs are an oral route of administration, the avoidance of the initial flare occurring with GnRH agonists, and a lower induced hypoestrogenic impact. In phase III clinical trials, elagolix (Elaris trials), linzagolix (Primrose trials), and relugolix (Liberty trials) have demonstrated excellent control of fibroid-related HMB, while also preserving bone mineral density in long-term regimens [45–47]. Recently, linzagolix has become the first GnRH antagonist approved by EMA at multiple doses (100–200 mg) with or without ABT for treating moderate-to-severe symptoms related to uterine fibroids. While at the lower dose associated with ABT this drug may be adopted for controlling symptoms in a long-term regimen, its short-term use (<6 months) at the higher dose without ABT could be indicated in women for whom ABT is not recommended or in clinical situations when a reduction of uterine and fibroid volume is primarily desired [47]. If, until now, the objective of studies on current pharmacological strategies for uterine fibroids has been to obtain only long-term symptom relief, the possibility of using GnRH antagonists with multiple dosing schedules with or without ABT opens up multiple clinical evaluations, including short-term

treatments to achieve a rapid volumetric reduction of fibroids. This possibility also presents an opportunity to evaluate medical strategies for improving fertility outcomes, both for spontaneous conception and assisted reproduction, in patients with uterine fibroids that may impair implantation.

High-Frequency Ablation Intervention and Nonsurgical Approaches

The intramural fibroids are a dilemma in the treatment of fibroids. In particular, intramural (FIGO type 3, 4, and 5, as FIGO type 2–5) fibroids are difficult to remove. With a hysteroscope, these fibroids cannot be reached, and a laparoscopic procedure will cause a uterine scar with a recovery time of several weeks [48].

Nowadays, women opt more and more for a minimal invasive treatment while retaining their uterus. Magnetic resonance-guided high-intensity focused ultrasound (HIFU) treatment, uterine artery embolization (UAE), and radiofrequency (RF) ablation technology are examples of nonsurgical minimally invasive treatments.

UAE has been evaluated in large RCTs with long follow-up. The Emmy trial compared UAE with hysterectomy up to 10 years of follow-up [49]. In about two-thirds of UAE-treated patients with symptomatic uterine fibroids, a hysterectomy could be avoided. Health-related quality of life after uterine artery embolization or hysterectomy remained comparably stable. The FEMME trial compared UAE with laparoscopic myomectomy [50]. Among women with symptomatic uterine fibroids, myomectomy resulted in greater improvement in quality of life than UAE. The differences in costs and quality-adjusted life-years were very small. Future research should involve women who are desiring pregnancy.

The HIFU technology has several implementations: MR-HIFU and ultrasound-guided HIFU. A systematic review of this technology for treating fibroids stated that HIFU could be an effective and safe treatment option for patients affected. However, one of its side effects, skin burns, requires further research and discussion. Additional studies involving more randomized controlled trials are warranted [51].

Last decade, high-frequency ablation has been implemented as a minimally invasive technology to treat fibroids [52, 53]. The ablation technology consists of radio frequent current. Different approaches have been described: laparoscopic, percutaneous, transvaginal and transcervical. All procedures are ultrasound-guided. All these techniques have been evaluated in a systematic

review [54], showing a consistent improvement of health-related quality of life and a reduction of symptoms after all RF ablation treatments. The transcervical RF ablation has been evaluated retrospectively showing high satisfaction; however, there was 24% of hysteroscopic re-intervention rate to remove the ablated fibroid tissue from the uterine cavity, after which the whole fibroid was removed [55].

Reproduction after the HIFU, UAE, and RF fibroid ablation has been evaluated in a systematic review [56]. The pooled estimate of pregnancies was 17.31–44.52% after UAE, 18.69–78.53% after HIFU, and 2.09–7.63% after RF ablation. These minimally invasive uterus-sparing treatment options for fibroids are a good approach for women with a future desire for pregnancy, with comparable reproductive outcomes among the different techniques. More research is needed to draw strong conclusions.

However, these three minimally invasive treatments have not been compared to each other in prospective or randomized trials. To compare results, it would be nice to have uniform core outcome parameters of fibroid treatment, so future studies would add more comparable outcomes, aiming to compare the satisfaction, reproduction outcome, effectiveness, and cost-effectiveness of these three minimally invasive techniques.

Management of Uterine Fibroids during Pregnancy

Uterine fibroids may increase the risk of adverse maternal-fetal outcomes, including miscarriage, preterm delivery, fetal growth restriction, fetal malpresentation, placental complications, and premature rupture of membranes [57, 58]. Furthermore, uterine fibroids are known to be associated with high risk of complications during labor and delivery, such as uterine atony, abnormalities of uterine contractile activity, and postpartum hemorrhage [59]. In addition, under the influence of hormonal changes of pregnancy, uterine fibroids can undergo colliquation and cause pelvic pain that often responds poorly to pharmacological approaches available for use during pregnancy [60]. Overall, the rate of uterine fibroid growth during pregnancy is still unclear: on the one hand, the increase of pregnancy-related hormones does not always cause an increase in the size of uterine fibroids [61]; on the other hand, a systematic review highlighted that uterine fibroids seem to undergo a nonlinear trend of modifications during pregnancy and puerperium, with a systematic enlargement during the first trimester of pregnancy, while inconsistent evidence is

available about the changes of uterine fibroids during second and third trimesters [62]. From the clinical point of view, submucosal fibroids as well as large intramural fibroids may have the most significant impact on pregnancy, due to mass-effect, compression of the intra-uterine space and, in case of fibroids placed below the placenta, they may be associated with reduced blood supply to the placental-fetal unit and cause fetal growth restriction as well as increased risk of placental abnormalities and abruption [63]. Conversely, subserosal fibroids, especially small ones, do not affect the uterine cavity environment and play only a minimal effect on pregnancy course. Nevertheless, large subserosal and intramural fibroids may both cause compression of the adjacent organs such as ureters (leading to hydro-ureteronephrosis), bladder (causing frequent urination and urgency), and bowel (leading to altered defecation) [64]. After the publication of the FIGO classification system (Fig. 1, see [27]), more data are now becoming available on FIGO type 3, characterized by its complete myometrial development while encroaching the endometrium [65]: indeed, accumulating evidence suggests that FIGO type 3 fibroids are significantly associated with a lower implantation rate, cumulative pregnancy rate, and live birth rate; furthermore, their deleterious effect on the outcome of IVF increases further with increasing size and number [66]. Considering the anatomical features of FIGO type 3 fibroids, an unique “hybrid” between a submucosal and an intramural fibroid, hysteroscopic approach may be considered a safe and feasible approach if performed by an expert gynecological endoscopist [67].

Among the limited approaches available for the management of fibroids during pregnancy, the use of acetylsalicylic acid for the management of pain is considered safe, whereas data about other painkillers are less robust to ensure safety [68]. Surgical approaches include myomectomy in case of cesarean section: although it may be associated in some cases with increased risk of severe uterine bleeding [69], a recent systematic review suggests that with appropriate hemostatic techniques and when performed by experienced surgeons, cesarean myomectomy may be safe and feasible in selected patients with fibroids, regardless of size and locations, except if they are located at the cornual area or close to large vessels and in the absence of uterine atony during surgery [70]. In addition, the presence of fibroids, as well as their size and location, should be carefully evaluated when a cesarean section is planned, since it may increase the surgical complexity due to their potential association with difficult access to the lower uterine segment, complicated fetal extraction, laceration or organ damage, and abnormal placentation [71].

In selected cases of uterine fibroids with severe symptoms when other treatment options have failed and there is high risk of adverse maternal-fetal outcomes, myomectomy during pregnancy could be considered as last resource [72] by laparotomy or even by laparoscopy (especially in case of subserosal/pedunculated fibroids) [73], although the risk/benefit ratio should be carefully evaluated since this procedure is associated with an increased risk of obstetric complications [74].

Hysteroscopic Myomectomy

The effect of fibroids on fertility depends on their size and location; moreover, fibroids may affect both reaching and maintaining a pregnancy [75]. The level of evidence published till today is scarce and based mostly on not randomized studies.

Based on the evidence, we know that subserosal fibroids do not appear to have an impact on fertility and that submucosal fibroids have been shown uniformly to have a negative impact on rates of implantation, clinical pregnancy, miscarriage, live birth/ongoing pregnancies [76].

The impact of intramural fibroids is controversial and again based on few studies with low level of evidence [77]. There is some evidence that supports the fact that intramural fibroids can lead to cavity involvement by making its distortion or being in contact with it [78], therefore potentially affecting fertility. Also, intramural fibroids of more >4 cm or multiple have a negative effect [79]. Thus, a surgical removal intramural fibroids of more than 4 cm, and especially of submucosal fibroids, could bring an improvement in fertility [80].

The approach for the removal of submucosal fibroids is by hysteroscopy techniques and based on finding the cleavage plane, specifically the pseudocapsule. It can be performed by resection, morcellation, or enucleation.

The enucleation process entails meticulous dissection along the pseudocapsule plane, particularly in FIGO type 1 or 2 fibroids, until the intramural segment of the fibroid achieves liberation [81, 82]. Subsequently, in instances such as FIGO type 0 fibroids, the fibroid may be allowed to reside freely within the uterine cavity following the cutting of the pedicle [83].

Why is it important to preserve the pseudocapsule in patients that wish to become pregnant? By dissecting through this plane the integrity of the myometrium is preserved, we avoid thermal damage or injury of the muscle and by this, we could reduce the risk of post-surgical fibrosis and synechia [84]. The surgical approach based on pseudocapsule preservation should become routine.

Laparoscopic Myomectomy

Laparoscopic myomectomy represents a minimally invasive and fertility-preserving approach, with clear benefits in term of faster recovery and better cosmetic outcomes compared with laparotomy, sharing the same indications (mainly symptoms/signs that are not resolved by pharmacological treatments).

Pharmacological preparation before laparoscopic myomectomy, including the administration of GnRH-a, could be useful to reduce fibroid volume and intraoperative blood loss, although the best strategy is yet to be elucidated [85].

In addition, different pharmacological (such as vaginal or rectal misoprostol, intramyometrial vasopressin injection, bupivacaine, and epinephrine subserosal injection, intravenous oxytocin infusion) hemostatic techniques proved to be useful to reduce intraoperative blood loss [41], although comparative analyses do not allow to identify the best strategy over the others, and we should take into account that intramyometrial vasopressin injection may cause adverse cardiopulmonary events. Similarly, some non-pharmacological hemostatic techniques, such as the use of tissue sealants [86], temporary uterine artery occlusion [87], and tourniquet loop [88], may also be considered adequate strategy to reduce intraoperative blood loss and, consequently, the need for transfusion and the risk of unplanned hysterectomy. From a technical perspective, both single-site [89] and robotic [90] approaches can be considered feasible and safe options: although both were not associated with longer operative time compared with standard laparoscopic myomectomy, robotic surgery is associated with higher costs. In addition, barbed sutures may be associated with better perioperative outcomes compared with conventional sutures [91]. Nevertheless, we currently need robust comparative analyses to evaluate reproductive and obstetric outcomes after single- versus multilayer suture; waiting for further and more robust evidence, we suggest suturing in as many layers as needed based on the depth of the defect. Robust data suggested that laparotomic approach and uterine cavity opening are associated with the risk of developing intrauterine adhesions [92], so these points should be taken into account during the counseling. After the warning of the Food and Drug Administration (FDA) in 2014 [93], it is mandatory to perform bag-contained specimen extraction in case of power morcellation: anyway, in-bag transvaginal extraction of the surgical specimens has comparable surgical outcomes than in-bag power morcellation [94]. Finally, laparoscopic myomectomy is not associated with

worse reproductive and obstetric outcomes compared with laparotomic approach [95], and vaginal delivery after laparoscopic myomectomy can be considered feasible and safe [96], with a waiting time for pregnancy of at least 3 months after surgery as precautionary measure to allow proper uterine healing and reduce the risk of uterine rupture.

How to Manage Unexpected Malignant Diseases

Myomectomy and hysterectomy for uterine fibroids represent the most common and widely performed gynecological surgical procedures worldwide. Different approaches may be used to perform these procedures: open, vaginal, or endoscopic (laparoscopic and robotic) surgery. Morcellation is a surgical technique that allows to decrease the size of the uterus or fibroids into smaller pieces to extract them through small incisions. The 2014 FDA warning underlined that about 0.3% of patients undergoing surgery for benign disease could have uterine sarcomas [97]. A 2017 review conducted by the Agency for Healthcare Research and Quality (AHRQ) estimated that the prevalence of unexpected uterine sarcoma is likely to be lower, showing that at the time of surgery for presumed symptomatic fibroids, the range was between <1 and up to 13 per 10,000 surgeries [98]. In June 2022, the FDA released an updated safety communication confirming these previous recommendations pointing out the importance of the use of tissue containment systems in order to minimize the risk of dissemination, although the safety of this procedure is still an object of investigation [99, 100]. Uncontained morcellation of unexpected uterine sarcomas can modify the natural history of the disease causing disseminated sarcomatosis, thus leading to worse oncologic survival outcomes compared to women whose lesions are extracted intact [101]. There is no clear evidence or guideline about the proper management of an uncontained morcellated unexpected malignancy after an endoscopic procedure. Surgical reexploration after morcellation is an option to ascertain the potential spread of the disease in the abdominal cavity; however, no definitive data are available to support this procedure, and no conclusive recommendation can be suggested [102, 103]. Among those patients who underwent myomectomy, radical surgery including hysterectomy should be offered [102, 103]. Data on the fertility-sparing treatment of patients after tumorectomy are scanty. Highly selected patients with early-stage disease (FIGO stage IA) may be candidate in tertiary referral

center after proper counseling and explaining that the procedure is experimental and cannot be considered as standard [37].

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

This article was not supported by any sponsor or funder.

References

- Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. *Nat Genet.* 1995;10(4):436–44.
- Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. *Science.* 2011;334(6053):252–5.
- Berta DG, Kuisma H, Välimäki N, Räisänen M, Jäntti M, Pasanen A, et al. Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma. *Nature.* 2021; 596(7872):398–403.
- Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, et al. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. *Cell Rep.* 2014;7(3):654–60.
- Buyukcelebi K, Chen X, Abdula F, Elkafas H, Duval AJ, Ozturk H, et al. Engineered MED12 mutations drive leiomyoma-like transcriptional and metabolic programs by altering the 3D genome compartmentalization. *Nat Commun.* 2023;14(1):4057.
- Tomlinson IPM, Alam NA, Rowan AJ, Barclay E, Jaeger EEM, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet.* 2002;30(4):406–10.
- Lehtonen R, Kiuru M, Vanharanta S, Sjöberg J, Aaltonen LM, Aittomäki K, et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. *Am J Pathol.* 2004;164(1):17–22.
- Mehine M, Ahvenainen T, Khamaiseh S, Härkönen J, Reinikka S, Heikkinen T, et al. A novel uterine leiomyoma subtype exhibits NRF2 activation and mutations in genes associated with neddylation of the Cullin 3-RING E3 ligase. *Oncogenesis.* 2022; 11(1):52.
- Mehine M, Kaasinen E, Mäkinen N, Katainen R, Kämpjärvi K, Pitkänen E, et al. Characterization of uterine leiomyomas by whole-genome sequencing. *N Engl J Med.* 2013;369(1):43–53.
- Mas A, Simón C. Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas. *Biol Reprod.* 2019;101(6): 1115–23.
- Mäkinen N, Kämpjärvi K, Frizzell N, Bützow R, Vahteristo P. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. *Mol Cancer.* 2017;16(1):101.
- Kommoss FKF, Stichel D, Schimpf D, Kriegsmann M, Tessier-Cloutier B, Talhouk A, et al. DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. *J Cancer Res Clin Oncol.* 2020;146(1):97–104.
- Machado-Lopez A, Alonso R, Lago V, Jimenez-Almazan J, Garcia M, Monleon J, et al. Integrative genomic and transcriptomic profiling reveals a differential molecular signature in uterine leiomyoma versus leiomyosarcoma. *Int J Mol Sci.* 2022; 23(4):2190.
- Marusyk A, Almendro V, Polyak K. Intratumour heterogeneity: a looking glass for cancer? *Nat Rev Cancer.* 2012;12(5):323–34.
- Raatz M, Shah S, Chitadze G, Brüggemann M, Traulsen A. The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamics. *PLoS Comput Biol.* 2021;17(2):e1008702.
- Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. *Nature.* 2021;596(7871): 211–20.
- Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, et al. Single-cell RNA sequencing in cancer research. *J Exp Clin Cancer Res.* 2021;40(1):81.
- Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. *J Exp Clin Cancer Res.* 2020; 39(1):95.
- De Bruyn C, Baert T, Van den Bosch T, Coosemans A. Circulating transcripts and biomarkers in uterine tumors: is there a predictive role? *Curr Oncol Rep.* 2020; 22(2):12.
- Di Cello A, Borelli M, Marra ML, Franzon M, D'Alessandro P, Di Carlo C, et al. A more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes' results in patients with uterine masses. *Eur J Obstet Gynecol Reprod Biol.* 2019;236: 143–7.
- Liu J, Wang Z. Advances in the preoperative identification of uterine sarcoma. *Cancers.* 2022;14(14):3517.
- Glorie N, Baert T, van Den Bosch T, Coosemans AN. Circulating protein biomarkers to differentiate uterine sarcomas from leiomyomas. *Anticancer Res.* 2019;39(8): 3981–9.
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science.* 2011;331(6024):1565–70.
- Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst.* 2014;106(6):dju124.
- Amant F, Van den Bosch T, Vergote I, Timmerman D. Morcellation of uterine leiomyomas: a plea for patient triage. *Lancet Oncol.* 2015;16(15):1454–6.
- Van den Bosch T, Dueholm M, Leone FPG, Valentin L, Rasmussen CK, Votino A, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. *Ultrasound Obstet Gynecol.* 2015;46(3): 284–98.

- 27 Munro MG, Critchley HOD, Broder MS, Fraser IS; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEN) for causes of abnormal uterine bleeding in nonpregnant women of reproductive age. *Int J Gynaecol Obstet*. 2011;113(1):3–13.
- 28 Frijling M, Juffermans L, de Leeuw R, de Bruyn C, Timmerman D, van den Bosch T, et al. How to use power Doppler ultrasound in transvaginal assessment of uterine fibroids. *Ultrasound Obstet Gynecol*. 2022;60(2):277–83.
- 29 Brölmann H, Tanos V, Grimbizis G, Ind T, Philips K, van den Bosch T, et al. Options on fibroid morcellation: a literature review. *Gynecol Surg*. 2015;12(1):3–15.
- 30 Ludovisi M, Moro F, Pasciuto T, Di Noi S, Giunchi S, Savelli L, et al. Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma. *Ultrasound Obstet Gynecol*. 2019;54(5):676–87.
- 31 Rasmussen CK, Van den Bosch T, Exacoustos C, Manegold-Brauer G, Benacerraf BR, Froyman W, et al. Intra- and inter-rater agreement describing myometrial lesions using morphologic uterus sonographic assessment: a pilot study. *J Ultrasound Med*. 2019;38(10):2673–83.
- 32 Exacoustos C, Romanini ME, Amadio A, Amoroso C, Szabolcs B, Zupi E, et al. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? *J Clin Ultrasound*. 2007;35(8):449–57.
- 33 Russo C, Camilli S, Martire FG, Di Giovanni A, Lazzari L, Malzoni M, et al. Ultrasound features of highly vascularized uterine myomas (uterine smooth muscle tumors) and correlation with histopathology. *Ultrasound Obstet Gynecol*. 2022;60(2):269–76.
- 34 Cabezas N, López-Picazo A, Diaz P, Valero B, Rodriguez MJ, Redondo A, et al. How frequently benign uterine myomas appear suspicious for sarcoma as assessed by transvaginal ultrasound? *Diagnostics*. 2023;13(3):501.
- 35 Suzuki A, Aoki M, Miyagawa C, Murakami K, Takaya H, Kotani Y, et al. Differential diagnosis of uterine leiomyoma and uterine sarcoma using magnetic resonance images: a literature review. *Healthcare*. 2019;7(4):158.
- 36 Lee JW, Park JY, Lee HJ, Lee JJ, Moon SH, Kang SY, et al. Preoperative [18F]FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study. *Eur J Nucl Med Mol Imaging*. 2018;45(8):1309–16.
- 37 Ferrandina G, Aristei C, Biondetti PR, Cananzi FCM, Casali P, Ciccarone F, et al. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società italiana di Ginecologia e Ostetricia). *Eur J Cancer*. 2020;139:149–68.
- 38 Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. *Hum Reprod Update*. 2016;22(6):665–86.
- 39 Sangkomkamhang US, Lumbiganon P, Pattanittum P. Progestogens or progesterone-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy). *Cochrane Database Syst Rev*. 2020;11(11):CD008994.
- 40 Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. *Contraception*. 2010;82(1):41–55.
- 41 Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. *Cochrane Database Syst Rev*. 2017;11(11):CD000547.
- 42 Broekmans FJ. GnRH agonists and uterine leiomyomas. *Hum Reprod*. 1996;11(Suppl 3):3–25.
- 43 Ferrero S, Vellone VG, Barra F, Scala C. Ulipristal acetate before hysteroscopic and laparoscopic surgery for uterine myomas: help or hindrance? *Gynecol Obstet Invest*. 2019;84(4):313–25.
- 44 Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. *Expert Opin Drug Metab Toxicol*. 2018;14(1):107–16.
- 45 Barra F, Seca M, Della Corte L, Giampaolino P, Ferrero S. Relugolix for the treatment of uterine fibroids. *Drugs Today*. 2019;55(8):503–12.
- 46 Barra F, Vitale SG, Seca M, Scala C, Leone Roberti Maggiore U, Cianci A, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas. *Expert Opin Pharmacother*. 2020;21(12):1419–30.
- 47 Dababou S, Garzon S, Laganà AS, Ferrero S, Evangelisti G, Noventa M, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. *Expert Opin Investig Drugs*. 2021;30(9):903–11.
- 48 Sinha R, Verma N, Bana R, Kalidindi N, Sampurna S, Mohanty GS. Intra- and post-operative outcomes in benign gynaecologic surgeries before and after the implementation of enhanced recovery after surgery protocols: a comparison. *J Minim Access Surg*. 2023;19(1):112–9.
- 49 de Bruijn AM, Ankum WM, Reekers JA, Birnie E, van der Kooij SM, Volkers NA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. *Am J Obstet Gynecol*. 2016;215(6):745.e1–745.e12.
- 50 Daniels J, Middleton LJ, Cheed V, McKinnon W, Rana D, Sirkeci F, et al. Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT. *Health Technol Assess*. 2022;26(22):1–74.
- 51 Tsai MC, Chang LT, Tam KW. Comparison of high-intensity focused ultrasound and conventional surgery for patients with uterine myomas: a systematic review and meta-analysis. *J Minim Invasive Gynecol*. 2021;28(10):1712–24.
- 52 Bongers M, Quinn SD, Mueller MD, Krämer B, Tuschy B, Sütterlin M, et al. Evaluation of uterine patency following transcervical uterine fibroid ablation with the Sonata system (the OPEN clinical trial). *Eur J Obstet Gynecol Reprod Biol*. 2019;242:122–5.
- 53 Turtulici G, Orlandi D, Dedone G, Mauri G, Fasciani A, Sirito R, et al. Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study. *Int J Hyperthermia*. 2019;35(1):97–104.
- 54 Bradley LD, Pasic RP, Miller LE. Clinical performance of radiofrequency ablation for treatment of uterine fibroids: systematic review and meta-analysis of prospective studies. *J Laparoendosc Adv Surg Tech*. 2019;29(12):1507–17.
- 55 van der Meulen JF, Cooijmans TH, van Zutven VJ, Leemans JC, Verhoeven CJ, Bongers MY. Long-term results of transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the sonata system: a retrospective follow-up study. *AJOG Glob Rep*. 2022;2(4):100087.
- 56 Akhatova A, Aimagambetova G, Bapayeva G, Laganà AS, Chiantera V, Oppelt P, et al. Reproductive and obstetric outcomes after UAE, HIFU, and TFA of uterine fibroids: systematic review and meta-analysis. *Int J Environ Res Public Health*. 2023;20(5):4480.
- 57 Parazzini F, Tozzi L, Bianchi S. Pregnancy outcome and uterine fibroids. *Best Pract Res Clin Obstet Gynaecol*. 2016;34:74–84.
- 58 Lee HJ, Norwitz ER, Shaw J. Contemporary management of fibroids in pregnancy. *Rev Obstet Gynecol*. 2010;3(1):20–7.
- 59 Ezzedine D, Norwitz ER. Are women with uterine fibroids at increased risk for adverse pregnancy outcome? *Clin Obstet Gynecol*. 2016;59(1):119–27.
- 60 Vitale SG, Tropea A, Rossetti D, Carnelli M, Cianci A. Management of uterine leiomyomas in pregnancy: review of literature. *Updates Surg*. 2013;65(3):179–82.
- 61 Selter JH, Price TM, Harris BS. Fibroids in pregnancy: a growing or shrinking issue? *Fertil Steril*. 2022;118(4):666–7.
- 62 Vitagliano A, Noventa M, Di Spazio Sardo A, Saccone G, Gizzo S, Borgato S, et al. Uterine fibroid size modifications during pregnancy and puerperium: evidence from the first systematic review of literature. *Arch Gynecol Obstet*. 2018;297(4):823–35.
- 63 Coutinho LM, Assis WA, Spagnuolo-Souza A, Reis FM. Uterine fibroids and pregnancy: how do they affect each other? *Reprod Sci*. 2022;29(8):2145–51.

- 64 Gupta S, Manyonda IT. Acute complications of fibroids. *Best Pract Res Clin Obstet Gynaecol.* 2009;23(5):609–17.
- 65 Favilli A, Mazzon I, Etrusco A, Dellino M, Laganà AS, Tinelli A, et al. The challenge of FIGO type 3 leiomyomas and infertility: exploring therapeutic alternatives amidst limited scientific certainties. *Int J Gynaecol Obstet.* 2023.
- 66 Favilli A, Etrusco A, Chiantera V, Laganà AS, Cicinelli E, Gerli S, et al. Impact of FIGO type 3 uterine fibroids on in vitro fertilization outcomes: a systematic review and meta-analysis. *Int J Gynaecol Obstet.* 2023; 163(2):528–39.
- 67 Etrusco A, Laganà AS, Chiantera V, Vitagliano A, Cicinelli E, Mikuš M, et al. Feasibility and surgical outcomes of hysteroscopic myomectomy of FIGO type 3 myoma: a systematic review. *J Clin Med.* 2023; 12(15):4953.
- 68 Powers EA, Tewell R, Bayard M. Over-the-Counter medications in pregnancy. *Am Fam Physician.* 2023;108(4):360–9.
- 69 Kwon JY, Byun JH, Shin I, Hong S, Kim R, Park IY. Risk factors for intraoperative hemorrhage during cesarean myomectomy. *Taiwan J Obstet Gynecol.* 2021;60(1):41–4.
- 70 Huang Y, Ming X, Li Z. Feasibility and safety of performing cesarean myomectomy: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med.* 2022;35(13): 2619–27.
- 71 Visconti F, Quaresima P, Rania E, Palumbo AR, Micieli M, Zullo F, et al. Difficult caesarean section: a literature review. *Eur J Obstet Gynecol Reprod Biol.* 2020; 246:72–8.
- 72 Babunashvili EL, Son DY, Buyanova SN, Schukina NA, Popov AA, Chechneva MA, et al. Outcomes of laparotomic myomectomy during pregnancy for symptomatic uterine fibroids: a prospective cohort study. *J Clin Med.* 2023;12(19): 6406.
- 73 Macciò A, Madeddu C, Kotsonis P, Caffiero A, Desogus A, Pietrangeli M, et al. Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas. *Arch Gynecol Obstet.* 2012;286(5):1209–14.
- 74 Loverro G, Damiani GR, Malvasi A, Loverro M, Schonauer LM, Muzzupapa G, et al. Myomectomy during pregnancy: an obstetric overview. *Minerva Obstet Gynecol.* 2021;73(5):646–53.
- 75 Somigliana E, Reschini M, Bonanni V, Busnelli A, Li Piani L, Vercellini P. Fibroids and natural fertility: a systematic review and meta-analysis. *Reprod Biomed Online.* 2021;43(1):100–10.
- 76 Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. *Fertil Steril.* 2009;91(4): 1215–23.
- 77 Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y, Coomarasamy A. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. *Hum Reprod.* 2010;25(2): 418–29.
- 78 Yan L, Yu Q, Zhang Y-N, Guo Z, Li Z, Niu J, et al. Effect of type 3 intramural fibroids on in vitro fertilization-intracytoplasmic sperm injection outcomes: a retrospective cohort study. *Fertil Steril.* 2018;109(5): 817–22.e2.
- 79 Galliano D, Bellver J, Díaz-García C, Simón C, Pellicer A. ART and uterine pathology: how relevant is the maternal side for implantation? *Hum Reprod Update.* 2015; 21(1):13–38.
- 80 Zepiridis LI, Grimbizis GF, Tarlatzis BC. Infertility and uterine fibroids. *Best Pract Res Clin Obstet Gynaecol.* 2016;34: 66–73.
- 81 Haimovich S, Mancebo G, Alameda F, Agramunt S, Solé-Sedeno JM, Hernández JL, et al. Feasibility of a new two-step procedure for office hysteroscopic resection of submucous myomas: results of a pilot study. *Eur J Obstet Gynecol Reprod Biol.* 2013; 168(2):191–4.
- 82 Mazzon I, Favilli A, Grasso M, Horvath S, Di Renzo GC, Gerli S. Is cold loop hysteroscopic myomectomy a safe and effective technique for the treatment of submucous myomas with intramural development? A series of 1434 surgical procedures. *J Minim Invasive Gynecol.* 2015;22(5):792–8.
- 83 Tanvir T, Garzon S, Alonso Pacheco L, Lopez Yarto M, Rios M, Stamenov G, et al. Office hysteroscopic myomectomy without myoma extraction: a multicenter prospective study. *Eur J Obstet Gynecol Reprod Biol.* 2021;256:358–63.
- 84 Tinelli A, Favilli A, Lasmar RB, Mazzon I, Gerli S, Xue X, et al. The importance of pseudocapsule preservation during hysteroscopic myomectomy. *Eur J Obstet Gynecol Reprod Biol.* 2019;243:179–84.
- 85 de Milliano I, Twisk M, Ket JC, Huirne JA, Hehenkamp WJ. Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: a systematic review and meta-analysis. *PLoS One.* 2017;12(10):e0186158.
- 86 Angioli R, Plotti F, Ricciardi R, Terranova C, Zullo MA, Damiani P, et al. The use of novel hemostatic sealant (Tisseel) in laparoscopic myomectomy: a case-control study. *Surg Endosc.* 2012;26(7): 2046–53.
- 87 Tranoulis A, Georgiou D, Alazzam M, Borley J. Combined laparoscopic uterine artery occlusion and myomectomy versus laparoscopic myomectomy: a direct-comparison meta-analysis of short- and long-term outcomes in women with symptomatic leiomyomas. *J Minim Invasive Gynecol.* 2019;26(5):826–37.
- 88 Kuo HH, Lin WL, Pai AH, Yen CF. Laparoscopic triple-tourniquet constriction: a convenient way for minimizing blood loss during myomectomy. *J Minim Invasive Gynecol.* 2022;29(11):1219–20.
- 89 Song T, Kim TJ, Lee SH, Kim TH, Kim WY. Laparoscopic single-site myomectomy compared with conventional laparoscopic myomectomy: a multicenter, randomized, controlled trial. *Fertil Steril.* 2015;104(5): 1325–31.
- 90 Wang T, Tang H, Xie Z, Deng S. Robotic-assisted vs. laparoscopic and abdominal myomectomy for treatment of uterine fibroids: a meta-analysis. *Minim Invasive Ther Allied Technol.* 2018;27(5):249–64.
- 91 Gardella B, Dominoni M, Iacobone AD, De Silvestri A, Tinelli C, Bogliolo S, et al. What is the role of barbed suture in laparoscopic myomectomy? A meta-analysis and pregnancy outcome evaluation. *Gynecol Obstet Invest.* 2018;83(6):521–32.
- 92 Laganà AS, Garzon S, Dababou S, Uccella S, Medvediev M, Pokrovenko D, et al. Prevalence of intrauterine adhesions after myomectomy: a prospective multicenter observational study. *Gynecol Obstet Invest.* 2022;87(1):62–9.
- 93 Brower V. FDA considers restricting or banning laparoscopic morcellation. *J Natl Cancer Inst.* 2014;106(10):dju339.
- 94 Laganà AS, Vitagliano A, Casarin J, Garzon S, Uccella S, Franchi M, et al. Transvaginal versus port-site specimen retrieval after laparoscopic myomectomy: a systematic review and meta-analysis. *Gynecol Obstet Invest.* 2022;87(3–4):177–83.
- 95 Metwally M, Raybould G, Cheong YC, Horne AW. Surgical treatment of fibroids for subfertility. *Cochrane Database Syst Rev.* 2020;1(1):CD003857.
- 96 Kumakiri J, Takeuchi H, Itoh S, Kitade M, Kikuchi I, Shimanuki H, et al. Prospective evaluation for the feasibility and safety of vaginal birth after laparoscopic myomectomy. *J Minim Invasive Gynecol.* 2008; 15(4):420–4.
- 97 ACOG Committee Opinion No. Uterine morcellation for presumed leiomyomas. *Obstet Gynecol.* 2019; 133(3):e238–48. 770.
- 98 Hartmann KE, Fonnesebeck C, Surawicz T, Krishnaswami S, Andrews JC, Wilson JE, et al. Management of uterine fibroids. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017. [cited 2023 Jul 5]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK537742/>.
- 99 Devassy R, Cezar C, Krentel H, Verhoeven HC, Devassy R, de Wilde MS, et al. Feasibility of myomatous tissue extraction in laparoscopic surgery by contained in-bag morcellation: a retrospective single arm study. *Int J Surg.* 2019;62:22–7.

- 100 Health and Human Services Food and Drug Administration Center for Devices and Radiological Health. Non-clinical performance assessment of tissue containment systems used during power morcellation procedures. US Food and Drug Administration; 2023. [cited 2023 Jul 5]. Available from: [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-performance-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-clinical-performance-assessment-tissue-containment-systems-used-during-power-morcellation)
- assessment-tissue-containment-systems-used-during-power-morcellation.
- 101 Xu X, Lin H, Wright JD, Gross CP, Boscoe FP, Hutchison LM, et al. Association between power morcellation and mortality in women with unexpected uterine cancer undergoing hysterectomy or myomectomy. *J Clin Oncol*. 2019;37(35):3412–24.
- 102 Bae J, Choi JS, Lee WM, Koh AR, Jung US, Ko JH, et al. Feasibility and efficacy of laparoscopic restaging surgery for women with unexpected ovarian malignancy. *Eur J Obstet Gynecol Reprod Biol*. 2015;193:46–50.
- 103 Kim EB, Hong HM, Lee WM, Choi JS, Bae JB, Jung US, et al. Laparoscopic systemic restaging surgery for women with unexpected uterine malignancy. *Obstet Gynecol Sci*. 2022;65(6):522–30.